Welcome: Guest | Site Use Options | Register | Login |

Yaupon Therapeutics Inc

Yaupon Therapeutics Inc

Profile last edited on: 2/19/2019
101 Lindenwood Drive Suite 400
Malvern, PA 19355
  (610) 975-9290
Business Identifier: Small molecule drug development: Rare cancers
Public Profile:
Doing business for over a decade as Yaupon Therapeutics, Inc, primarily organized around IP licensed from the University of Kentucky, the firm has been working on utilizing transdermal delivery technology to deliver S-(-)-nornicotine through skin for the treatment of nicotine dependence. Plants had for centuries been known a repository of naturally occurring compounds to treat disease. Yaupon was applying modern techniques to identify valuable medicines that address unmet medical needs. In January 2012, the firm changed its name to Ceptaris Therapeutics Inc. and shifted focus to development of mechlorethamine gels using a formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. By September 2013, Ceptaris Therapeutics Inc. was acquired and operates as a subsidiary of Actelion US Holding Company.

 Synopsis: Awardee Business Condition
Year Founded First SBIR Year Date of Last Award
Employee Range VC funded? IP Holdings
Revenue Range Private/Public Exchange/Symbol :

Unlock access

To unlock access to all SBIR-STTR company Profiles, a FREE site registration is required. Click here to register or login if you already have an account

Smart Office Options

SBIR firms in the news


Is this YOUR Company?

Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached

Do you know about this Awardees?

Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Contact information

Innovation Development Institute, LLC

   45 Beach Bluff Avenue, Suite 300
     Swampscott,  MA 01907-1542

  Tel:  (781) 595-2920